164 related articles for article (PubMed ID: 12211096)
1. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
Yamada Y; Ohno Y; Nakashima Y; Fukuda M; Takayanagi R; Sato H; Tsuchiya F; Sawada Y; Iga T
Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
4. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
5. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable.
Medori R; Mannaert E; Gründer G
Eur Neuropsychopharmacol; 2006 May; 16(4):233-40. PubMed ID: 16326078
[TBL] [Abstract][Full Text] [Related]
6. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
7. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
[TBL] [Abstract][Full Text] [Related]
8. Markers of D(2) and D(3) receptor activity in vivo: PET scan and prolactin.
Thomasson-Perret N; Pénélaud PF; Théron D; Gouttefangeas S; Mocaër E
Therapie; 2008; 63(3):237-42. PubMed ID: 18718212
[TBL] [Abstract][Full Text] [Related]
9. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
10. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Matsui-Sakata A; Ohtani H; Sawada Y
Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
[TBL] [Abstract][Full Text] [Related]
12. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
[TBL] [Abstract][Full Text] [Related]
13. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
14. Neuroleptic malignant syndrome with risperidone.
Gleason PP; Conigliaro RL
Pharmacotherapy; 1997; 17(3):617-21. PubMed ID: 9165568
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
[TBL] [Abstract][Full Text] [Related]
16. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Knable MB; Heinz A; Raedler T; Weinberger DR
Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
[TBL] [Abstract][Full Text] [Related]
18. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
[TBL] [Abstract][Full Text] [Related]
19. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Kapur S; Remington G; Zipursky RB; Wilson AA; Houle S
Life Sci; 1995; 57(10):PL103-7. PubMed ID: 7543969
[TBL] [Abstract][Full Text] [Related]
20. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
Uchida H; Mamo DC; Pollock BG; Suzuki T; Tsunoda K; Watanabe K; Mimura M; Bies RR
Ther Drug Monit; 2012 Apr; 34(2):182-7. PubMed ID: 22377743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
